MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia.
Doralina do Amaral RabelloVivian D'Afonseca da Silva FerreiraMaria Gabriela Berzoti-CoelhoSandra Mara BurinCíntia Leticia MagroMaira da Costa CacemiroBelinda Pinto SimõesFelipe Saldanha-AraujoFabíola Attié de CastroFabio Pittella-SilvaPublished in: Cancer cell international (2018)
Our results established a new association between MLL2/KMT2D and MLL3/KMT2C genes with CML and suggest that MLL2/KMT2D is associated with disease evolution and may be a potential marker to predict the development of therapy resistance.